|Home | Data | Statistics | Tools | Collaborations | Work with Us | Publications | About | Links|
Performance Measures for 1,838,372 Screening Mammography Examinations1 from 2004 to 2008 by Age -- based on BCSC data through 2009
You are viewing the 2009 collection of this data. Data from other times are also available:
1 Screening mammography examinations: Mammography examinations indicated by the radiologist to be for screening with bilateral routine views done and no other mammogram within the last 9 months among women without breast implants or a prior mastectomy or a prior breast cancer diagnosis.
4 Recall = The percentage of examinations with a positive initial interpretation&.
7 PPV3 = The percentage of examinations with a positive final interpretation^, where it is known that a biopsy was performed as a result of the positive interpretation, that result in a tissue diagnosis of cancer within one year.
§ Cancers = Examinations with a tissue diagnosis of ductal carcinoma insitu or invasive cancer within one year and before the next screening mammography examination.
~ Non-cancers = Examinations without a tissue diagnosis of cancer within one year or before the next screening examination, whichever occurs earlier.
& Positive initial interpretation = BI-RADS category 0, 4, or 5 (Note: category 3 with a recommendation for immediate follow-up was recoded as category 0).
# Negative initial interpretation = BI-RADS category 1, 2, or 3 with no recommendation for immediate follow-up.
^ Positive final interpretation = BI-RADS category 4 or 5 (Note: categories 0 and 3 with a recommendation for biopsy were recoded as category 4).
Table numbers last updated September 23, 2013. The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/.
Last modified: 09 Jul 2014
Contact Us | Accessibility | Viewing Files | Policies
|Maintained by the
Healthcare Delivery Research Program,
Division of Cancer Control and Population Sciences